Reviewing NewLink Genetics Corporation (NLNK)’s and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)’s results

We are contrasting NewLink Genetics Corporation (NASDAQ:NLNK) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) on their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NewLink Genetics Corporation 12.47M 5.71 53.59M -1.53 0.00
Progenics Pharmaceuticals Inc. 15.62M 23.92 67.66M -0.78 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of NewLink Genetics Corporation and Progenics Pharmaceuticals Inc.

Profitability

Table 2 represents NewLink Genetics Corporation (NASDAQ:NLNK) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
NewLink Genetics Corporation -429.75% -52.1% -44.2%
Progenics Pharmaceuticals Inc. -433.16% -73.7% -36.4%

Volatility & Risk

A 1.84 beta means NewLink Genetics Corporation’s volatility is 84.00% more than Standard & Poor’s 500’s volatility. Progenics Pharmaceuticals Inc. has a 2.42 beta and it is 142.00% more volatile than Standard & Poor’s 500.

Liquidity

NewLink Genetics Corporation’s Current Ratio is 13.3 while its Quick Ratio is 13.3. On the competitive side is, Progenics Pharmaceuticals Inc. which has a 9.5 Current Ratio and a 9.5 Quick Ratio. NewLink Genetics Corporation is better positioned to pay off short and long-term obligations compared to Progenics Pharmaceuticals Inc.

Analyst Recommendations

The table delivered features the ratings and recommendations for NewLink Genetics Corporation and Progenics Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
NewLink Genetics Corporation 1 1 0 2.50
Progenics Pharmaceuticals Inc. 0 0 2 3.00

NewLink Genetics Corporation has an average price target of $4.5, and a 135.60% upside potential. Meanwhile, Progenics Pharmaceuticals Inc.’s average price target is $9.25, while its potential upside is 109.28%. Based on the data delivered earlier, NewLink Genetics Corporation is looking more favorable than Progenics Pharmaceuticals Inc., analysts belief.

Institutional and Insider Ownership

Institutional investors held 34.8% of NewLink Genetics Corporation shares and 85.2% of Progenics Pharmaceuticals Inc. shares. Insiders held 1% of NewLink Genetics Corporation shares. Comparatively, insiders own roughly 0.3% of Progenics Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
NewLink Genetics Corporation 11.04% 21.48% -4.74% -41.42% -74.11% 19.08%
Progenics Pharmaceuticals Inc. -0.68% -0.68% -16.19% -44.51% -33.53% 4.76%

For the past year NewLink Genetics Corporation was more bullish than Progenics Pharmaceuticals Inc.

Summary

On 7 of the 12 factors NewLink Genetics Corporation beats Progenics Pharmaceuticals Inc.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. Its portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. The company is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer (NSCLC); and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors. Its clinical development products include NLG2101 for metastatic breast cancer; NLG2102 for refractory malignant brain tumors; NLG2103 for advanced melanoma; NLG2104 for metastatic pancreatic cancer; NLG2105 for pediatric patients with refractory malignant brain tumors; and NLG2106 for acute myelogenous leukemia. The companyÂ’s HyperAcute cellular immunotherapy product candidates under clinical development include tergenpumatucel-L, is being investigated in Phase Ib/II clinical trial for patients with advanced NSCLC; and dorgenmeltucel-L, is being investigated in a Phase II clinical trial for patients with advanced melanoma. Its infectious disease program includes replication-competent recombinant vesicular stomatitis virus, a vaccine technology to treat Ebola and Marburg viruses. The company has license and collaboration agreements with Genentech, Inc. and Merck, Sharpe and Dohme Corp. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient, as well as for treatment of OIC in patients with non-cancer pain; and Relistor-oral tablets for the treatment of OIC. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York, New York.